K-Dur
K-Dur treats low potassium. We think.

Since 2003, the Federal Trade Commission has fought a losing battle to halt bargains in which a brand-name drug-maker pays a generic competitor to put off entering the market. Pacts like that, the agency urged, result in "reverse payments", which compensate a patent infringer not to do stuff that might infringe the patent. Such arrangements violate antitrust law

For people who lose a claim of confidential lawyer-client communication or work product privilege, the normal rule gives them a scary option if they want to contest the loss in a higher court. They must defy the order, which directs them to produce the documents or furnish the information, and thus stand in contempt of